The UCLA Vine Street Clinic (UVSC) was established in 2005 in order to study the diffusion of HIV among methamphetamine user networks. Since that time, it has served as a site for clinical trials, behavioral research, and direct services focusing on the treatment of addiction, HIV prevention, and the intersection of the two. It is unique in its location, bringing the best in academia from UCLA into a transitional neighborhood of predominately working poor, an area designated as a medically underserved. The facility includes exam and counseling rooms for patient care, a lab for collection and storage of biological samples, and group meeting space. Current services available at the clinic are detailed below.
For more information or to schedule an appointment, call us at (323) 461-3106 or email us at email@example.com.
Our Current Programs Include:
RELEVANCE: PrEP agents are needed that do not depend on daily or near-daily pill-taking. The development of alternative agents for PrEP, and/or more adherence-friendly schedules for currently available agents, could increase prevention choices and increase acceptability. Long-acting injectable agents have the potential to prevent HIV acquisition without relying on adherence to a daily oral regimen.
DESCRIPTION: Once randomized to one of two arms, participants will move through the steps below and followed for up to 4 and a half years:
Arm A – Daily oral CAB (30 mg tablets) and oral TDF/FTC placebo for five weeks
Arm B – Daily oral TDF/FTC (300 mg/200 mg fixed-dose combination tablets) and oral CAB placebo for five weeks
A participant that becomes HIV-infected during Step 1 of the study will permanently discontinue study product and will be terminated from the study, and referred for HIV-related care.
Arm A – CAB LA (600 mg as a single intramuscular [IM] injection at two time points 4 weeks apart and every 8 weeks thereafter) and daily oral TDF/FTC placebo.
Arm B – Daily oral TDF/FTC (300/200 mg fixed-dose combination tablets) and IM placebo at two time points 4 weeks apart and every 8 weeks thereafter (matching vehicle, identical volume as active injectable product in Arm A).
This step will continue until the required number of endpoints is reached.
A participant that becomes HIV-infected during Step 2 of the study will permanently discontinue study product, be placed on immediate suppressive ART, and be followed for 52 weeks after their last injection, after which their participation in the study will end and they will be transitioned to continued HIV-related care.
Both arms: Open-label daily oral TDF/FTC no later than 8 weeks after the last injection (in order to cover the pharmacokinetic (PK) tail for Arm A participants), for up to 48 weeks.
Participants will then transition to locally-available HIV prevention services, including services for PrEP, if available.
A participant with confirmed HIV infection during Step 3 will be followed at least for the duration of Step 3.
STATUS: Preliminary results can be reviewed at this link.
RELEVANCE: SARS-CoV-2 is the virus that causes the disease called COVID-19, short for “Coronavirus Disease of 2019”. Finding an effective vaccine for COVID-19 is one of several steps being taken to end this global pandemic.
DESCRIPTION: The purpose of this study is to test Moderna’s vaccine candidate (mRNA-1273) to see if it can prevent illness if people are exposed to the SARS-CoV-2 virus in their everyday lives. This vaccine is not made from the SARS-CoV-2 virus. It is made from messenger ribonucleic acid (mRNA), a genetic code that tells cells how to make protein, which helps the body’s immune system make antibodies that can fight the virus. The vaccine cannot cause COVID-19 infection. This Phase 3 trial is being conducted at multiple clinic sites across the U.S. with a goal of enrolling 30,000 patients. Trial participants will receive 2 injections, approximately 28 days apart and will complete regular follow ups over the course of two years via phone calls, on-line surveys and additional in-person visits.
STATUS: This study is still active, but no longer enrolling new patients. Results of an interim analysis were released on November 16 and can be found here: https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy.
RELEVANCE: Stimulant use, especially among men who have sex with men (MSM) in Los Angeles County (LAC) is common. Stimulant drug use, particularly methamphetamine use, is a significant factor in the progression of HIV and STI among MSM in LAC. Non-white MSM are at greatest risk of HIV infection in the United States. Analyses of drug use are needed among diverse samples of MSM in order to understand the impact of drug use on the HIV epidemic over time and to address the effect of long-term drug use patterns on uptake and adherence to treatment and prevention of the disease.
DESCRIPTION: The goal of this project is to assemble a cohort of minority men who have sex with men (MMSM) who actively use substances and engage transmission risks. This will facilitate studies on interactions between substance use and HIV progression and/or transmission. This important cohort of MMSM will characterize: (i) effects substance use on risk behaviors, and network dynamics in exposed and infected MMSM on acquisition of HIV and other sexually transmitted infections (STIs: gonorrhea, Chlamydia, syphilis, Hepatitis C (HCV)); and (ii) the extent to which substance use in MMSM facilitates behaviors that transmit HIV compared to non-drug using MMSM.
STATUS: This study is not currently enrolling. For more information, visit the study website at http://www.theMStudy.org.
According to a 1992 study published in the Journal of Sexually Transmitted Diseases, using a condom makes sex 10,000 times safer than not using a condom. The UCLA Vine Street Clinic has partnered with LA County to provide free condoms to the public. For more information, visit http://lacondom.com/find-free-condoms/